{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T16:03:24Z","timestamp":1777737804458,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia"},{"DOI":"10.13039\/501100021538","name":"Universidade Lus\u00f3fona de Humanidades e Tecnologias","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021538","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40261-023-01291-6","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T20:25:44Z","timestamp":1689971144000},"page":"691-698","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence"],"prefix":"10.1007","volume":"43","author":[{"given":"In\u00eas Soares","family":"de Pinho","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3905-0238","authenticated-orcid":false,"given":"Paulo","family":"Luz","sequence":"additional","affiliation":[]},{"given":"Lucy","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Lopes-Br\u00e1s","sequence":"additional","affiliation":[]},{"given":"Vanessa","family":"Patel","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Esperan\u00e7a-Martins","sequence":"additional","affiliation":[]},{"given":"Lisa","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Ritas","family":"Freitas","sequence":"additional","affiliation":[]},{"given":"Diana","family":"Sim\u00e3o","sequence":"additional","affiliation":[]},{"given":"Maria Rold\u00e1n","family":"Galnares","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Silvia Artacho","family":"Criado","sequence":"additional","affiliation":[]},{"given":"Salvador Gamez","family":"Casado","sequence":"additional","affiliation":[]},{"given":"Jose Baena","family":"Ca\u00f1ada","sequence":"additional","affiliation":[]},{"given":"Isabel M. Saffie","family":"Vega","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o G.","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Ana S.","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Rita Teixeira","family":"de Sousa","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Costa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"issue":"4","key":"1291_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000492122","volume":"13","author":"S Escriv\u00e1-de-Roman\u00ed","year":"2018","unstructured":"Escriv\u00e1-de-Roman\u00ed S, Arum\u00ed M, Zamora E, Bellet M. Neoadjuvant model as a platform for research in breast cancer and novel targets under development in this field. Breast Care (Basel). 2018;13(4):251\u201362. https:\/\/doi.org\/10.1159\/000492122.","journal-title":"Breast Care (Basel)."},{"key":"1291_CR2","doi-asserted-by":"publisher","unstructured":"Cortazar P, Zhang L, Untch M, et\u00a0al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [published correction appears in Lancet. 2019 Mar 9;393(10175):986].\u00a0Lancet. 2014;384(9938):164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","DOI":"10.1016\/S0140-6736(13)62422-8"},{"issue":"1","key":"1291_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, et\u00a0al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(21)00589-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1291_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/bjc.2015.426","volume":"114","author":"AS Hamy","year":"2016","unstructured":"Hamy AS, Belin L, Bonsang-Kitzis H, Paquet C, Pierga JY, Lerebours F, et\u00a0al. Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. Br J Cancer. 2016;114(1):44\u201352. https:\/\/doi.org\/10.1038\/bjc.2015.426.","journal-title":"Br J Cancer"},{"issue":"8","key":"1291_CR5","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et\u00a0al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2019;30(8):1194\u2013220. https:\/\/doi.org\/10.1093\/annonc\/mdz173.","journal-title":"Ann Oncol"},{"issue":"6","key":"1291_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et\u00a0al. Breast cancer, Version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691\u2013722. https:\/\/doi.org\/10.6004\/jnccn.2022.0030.","journal-title":"J Natl Compr Canc Netw"},{"issue":"18","key":"1291_CR7","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1200\/jco.2005.05.029","volume":"23","author":"C Praga","year":"2005","unstructured":"Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, et\u00a0al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005;23(18):4179\u201391. https:\/\/doi.org\/10.1200\/jco.2005.05.029.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1291_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tcm.2019.01.006","volume":"30","author":"A Padegimas","year":"2020","unstructured":"Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med. 2020;30(1):22\u20138. https:\/\/doi.org\/10.1016\/j.tcm.2019.01.006.","journal-title":"Trends Cardiovasc Med"},{"issue":"12","key":"1291_CR9","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/s1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentj\u00e9 VO, et\u00a0al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630\u201340. https:\/\/doi.org\/10.1016\/s1470-2045(18)30570-9.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1291_CR10","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et\u00a0al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278\u201384. https:\/\/doi.org\/10.1093\/annonc\/mdt182.","journal-title":"Ann Oncol"},{"issue":"2","key":"1291_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et\u00a0al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1406281.","journal-title":"N Engl J Med"},{"issue":"22","key":"1291_CR12","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1200\/jco.19.00066","volume":"37","author":"SM Tolaney","year":"2019","unstructured":"Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et\u00a0al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2019;37(22):1868\u201375. https:\/\/doi.org\/10.1200\/jco.19.00066.","journal-title":"J Clin Oncol"},{"key":"1291_CR13","doi-asserted-by":"crossref","unstructured":"Slamon D, Eiermann W, Robert N, Giermek J, Martin M, Jasiowka M, editors. Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC [right arrow] T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC [right arrow] TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. In: Oral presentation at San Antonio breast cancer symposium; 2015.","DOI":"10.1158\/1538-7445.SABCS15-S5-04"},{"issue":"4_Supplement","key":"1291_CR14","doi-asserted-by":"publisher","first-page":"PD3-05","DOI":"10.1158\/1538-7445.SABCS20-PD3-05","volume":"81","author":"AG Waks","year":"2021","unstructured":"Waks AG, Desai NV, Li T, Poorvu PD, Partridge AH, Sinclair N, et\u00a0al. Abstract PD3-05: The DAPHNE trial: a feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer. Cancer Res. 2021;81(4_Supplement):PD3-05.","journal-title":"Cancer Res"},{"key":"1291_CR15","doi-asserted-by":"publisher","first-page":"100483","DOI":"10.1016\/j.ctarc.2021.100483","volume":"29","author":"S Arora","year":"2021","unstructured":"Arora S, Gogia DA, Deo S, Sharma D, Mathur SR. Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline-free chemotherapy regimen in patients with HER2 positive breast cancer-real-world data from a single center in India. Cancer Treat Res Commun. 2021;29:100483. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100483.","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"1291_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.4143\/crt.2021.901","volume":"54","author":"JY Kim","year":"2022","unstructured":"Kim JY, Nam SJ, Lee JE, Yu J, Chae BJ, Lee SK, et\u00a0al. Real world evidence of neoadjuvant docetaxel\/carboplatin\/trastuzumab\/pertuzumab (TCHP) in patients with HER2-positive early or locally advanced breast cancer: a single-institutional clinical experience. Cancer Res Treat. 2022;54(4):1091\u20138. https:\/\/doi.org\/10.4143\/crt.2021.901.","journal-title":"Cancer Res Treat"},{"issue":"11","key":"1291_CR17","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/annonc\/mdx494","volume":"28","author":"UA Nitz","year":"2017","unstructured":"Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Kuemmel S, et\u00a0al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+\/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab \u00b1 weekly paclitaxel. Ann Oncol. 2017;28(11):2768\u201372. https:\/\/doi.org\/10.1093\/annonc\/mdx494.","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"1291_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1200\/JCO.2021.39.15_suppl.503","volume":"39","author":"N Harbeck","year":"2021","unstructured":"Harbeck N, Gluz O, Christgen M, Kuemmel S, Grischke E-M, Braun M, et\u00a0al. De-escalated neoadjuvant pertuzumab + trastuzumab with or without paclitaxel weekly in HR\u2212\/HER2+ early breast cancer: ADAPT-HR\u2212\/HER2+ biomarker and survival results. J Clin Oncol. 2021;39(15_suppl):503. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.503.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1291_CR19","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1200\/jco.2013.53.1608","volume":"32","author":"I Vaz-Luis","year":"2014","unstructured":"Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, et\u00a0al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32(20):2142\u201350. https:\/\/doi.org\/10.1200\/jco.2013.53.1608.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1291_CR20","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1200\/jco.2013.52.0858","volume":"32","author":"L Fehrenbacher","year":"2014","unstructured":"Fehrenbacher L, Capra AM, Quesenberry CP Jr, Fulton R, Shiraz P, Habel LA. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014;32(20):2151\u20138. https:\/\/doi.org\/10.1200\/jco.2013.52.0858.","journal-title":"J Clin Oncol"},{"issue":"34","key":"1291_CR21","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.1200\/jco.2009.22.0962","volume":"27","author":"G Curigliano","year":"2009","unstructured":"Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, et\u00a0al. Clinical relevance of HER2 overexpression\/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 2009;27(34):5693\u20139. https:\/\/doi.org\/10.1200\/jco.2009.22.0962.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1291_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et\u00a0al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25\u201332. https:\/\/doi.org\/10.1016\/s1470-2045(11)70336-9.","journal-title":"Lancet Oncol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01291-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01291-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01291-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T03:35:53Z","timestamp":1695353753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01291-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01291-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"3 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author name should be Paulo Luz instead of Paulo Luz\u2019\u2019","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by FCT|FCCN (b-on). The study was funded by Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia\u2014Portugal (Grants UIDB\/04567\/2020 and UIDP\/04567\/2020 to CBIOS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None of the authors has any conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures in this study were in accordance with the 1964 Helsinki Declaration (and its amendments). Ethics Committee approval number and date of approval: Centro Hospitalar Universit\u00e1rio do Algarve: Ref\u00aa 48\/2019, 28\/10\/2019. Hospital de Santa Maria, CHULN, Lisbon, Portugal: Ref\u00aa. N\u00ba 297\/22, 17\/02\/2023. Hospital Prof. Dr. Fernando Fonseca, Amadora, Portugal: Ref 85\/2022, 14\/09\/2022. Centro Hospitalar Lisboa Central, Lisbon, Portugal: not available. Hospital Virgen de Valme, Seville, Spain. RDA-PER-2019-01, 04\/06\/2019. Centro Hospitalar Barreiro-Montijo, Barreiro, Portugal. Ref 27\/2020, 16\/10\/2020. Hospital Universit\u00e1rio Puerta del Mar, C\u00e1diz, Spain: not available. Fundaci\u00f3n Arturo L\u00f3pez P\u00e9rez, Chile: Ref 10\/2021, 20\/10\/2021.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable\u00a0as anonymized data were retrospectively\u00a0collected from electronic clinical records.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"I.P.: investigation, methodology, writing\u2014original draft preparation; P.L.: investigation, methodology, writing\u2014original draft preparation; L.A., R.L.B., V.P., M.E.M., L.G., R.F., D.M., M.R.G., I.F., S.A.C., S.G., and J.B.C.: investigation; I.S.V.: investigation; J.G.C. and A.S.F.: supervision, writing\u2014review and editing; R.T.S. and L.C.: supervision, validation.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}